ERBB2 and breast carcinoma: Conversely, several combinations of a mAb with cytotoxics have resulted in a major increase in efficacy (e.g., anti-Her2 trastuzumab with taxanes or anthracyclins for Her-2 breast cancers [83]) or more modest improvement (e.g., anti-EGFR cetuximab [84] or anti-VEGFA bevacizumab [85] combined with cytotoxics for treating colorectal cancers).